Monopar Therapeutics Inc. Net Income
Monopar Therapeutics Inc. (MNPR) reported Net Income of -$5.31 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-12
- Monopar Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$5.31M.
- Monopar Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$3.89M.
- Monopar Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$5.20M.
- Monopar Therapeutics Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$3.44M.
- Monopar Therapeutics Inc. net income (loss) attributable to parent for fiscal 2022 was -$10.52M.
- Monopar Therapeutics Inc. net income (loss) attributable to parent for fiscal 2021 was -$9.10M.
- Monopar Therapeutics Inc. net income (loss) attributable to parent for fiscal 2020 was -$6.30M.
- Monopar Therapeutics Inc. net income (loss) attributable to parent for fiscal 2019 was -$4.22M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$5.31M 10-Q · filed 2026-08-12 | -$9.21M 10-Q · filed 2026-08-12 | -$14.41M derived: sum of 3 quarters · filed 2026-08-12 | -$17.84M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2026-03-31 | -$3.89M 10-Q · filed 2026-08-12 | -$9.09M derived: sum of 2 quarters · filed 2026-08-12 | -$12.53M derived: sum of 3 quarters · filed 2026-08-12 | -$14.99M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-12-31 | -$5.20M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | -$8.64M derived: sum of 2 quarters · filed 2026-04-30 | -$11.09M derived: sum of 3 quarters · filed 2026-08-12 | -$13.72M DEF 14A · filed 2026-04-30 | -$13.72M 10-K · filed 2026-03-27 | |
| 2025-09-30 | -$3.44M 10-Q · filed 2025-11-13 | -$5.89M derived: sum of 2 quarters · filed 2026-08-12 | -$8.52M 10-Q · filed 2025-11-13 | -$19.44M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-06-30 | -$2.45M 10-Q · filed 2026-08-12 | -$5.08M 10-Q · filed 2026-08-12 | -$16.00M derived: sum of 3 quarters · filed 2026-08-12 | -$17.31M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | -$2.62M 10-Q · filed 2026-08-12 | -$13.55M derived: sum of 2 quarters · filed 2026-08-12 | -$14.85M derived: sum of 3 quarters · filed 2026-08-12 | -$16.57M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2024-12-31 | -$10.93M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | -$12.23M derived: sum of 2 quarters · filed 2026-04-30 | -$13.94M derived: sum of 3 quarters · filed 2026-04-30 | -$15.59M DEF 14A · filed 2026-04-30 | -$15.59M 10-K · filed 2025-03-31 | |
| 2024-09-30 | -$1.30M 10-Q · filed 2025-11-13 | -$3.02M derived: sum of 2 quarters · filed 2025-11-13 | -$4.66M 10-Q · filed 2025-11-13 | -$6.47M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2024-06-30 | -$1.72M 10-Q · filed 2025-11-13 | -$3.36M 10-Q · filed 2025-08-12 | -$5.17M derived: sum of 3 quarters · filed 2026-04-30 | -$7.12M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2024-03-31 | -$1.64M 10-Q · filed 2025-11-13 | -$3.45M derived: sum of 2 quarters · filed 2026-04-30 | -$5.41M derived: sum of 3 quarters · filed 2026-04-30 | -$7.61M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2023-12-31 | -$1.81M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-30 | -$3.77M derived: sum of 2 quarters · filed 2026-04-30 | -$5.97M derived: sum of 3 quarters · filed 2026-04-30 | -$8.40M DEF 14A · filed 2026-04-30 | -$8.40M 10-K · filed 2024-03-28 | |
| 2023-09-30 | -$1.95M 10-Q · filed 2024-11-08 | -$4.15M derived: sum of 2 quarters · filed 2024-11-08 | -$6.59M 10-Q · filed 2024-11-08 | -$9.48M derived: sum of 4 quarters · filed 2024-11-08 | ||
| 2023-06-30 | -$2.20M 10-Q · filed 2024-11-08 | -$4.63M 10-Q · filed 2024-08-09 | -$7.53M derived: sum of 3 quarters · filed 2024-11-08 | -$9.93M derived: sum of 4 quarters · filed 2024-11-08 | ||
| 2023-03-31 | -$2.43M 10-Q · filed 2024-11-08 | -$5.33M derived: sum of 2 quarters · filed 2024-11-08 | -$7.73M derived: sum of 3 quarters · filed 2024-11-08 | -$10.49M derived: sum of 4 quarters · filed 2024-11-08 | ||
| 2022-12-31 | -$2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$5.30M derived: sum of 2 quarters · filed 2024-03-28 | -$8.06M derived: sum of 3 quarters · filed 2024-03-28 | -$10.52M 10-K · filed 2024-03-28 | ||
| 2022-09-30 | -$2.40M 10-Q · filed 2023-11-09 | -$5.16M derived: sum of 2 quarters · filed 2023-11-09 | -$7.62M 10-Q · filed 2023-11-09 | -$10.30M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | -$2.76M 10-Q · filed 2023-11-09 | -$5.22M 10-Q · filed 2023-08-10 | -$7.90M derived: sum of 3 quarters · filed 2023-11-09 | -$10.36M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-03-31 | -$2.46M 10-Q · filed 2023-11-09 | -$5.14M derived: sum of 2 quarters · filed 2023-11-09 | -$7.60M derived: sum of 3 quarters · filed 2023-11-09 | -$9.68M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2021-12-31 | -$2.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$5.14M derived: sum of 2 quarters · filed 2023-03-23 | -$7.22M derived: sum of 3 quarters · filed 2023-03-23 | -$9.10M 10-K · filed 2023-03-23 | ||
| 2021-09-30 | -$2.46M 10-Q · filed 2022-11-10 | -$4.54M derived: sum of 2 quarters · filed 2022-11-10 | -$6.42M 10-Q · filed 2022-11-10 | -$8.55M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | -$2.08M 10-Q · filed 2022-08-11 | -$3.96M 10-Q · filed 2022-08-11 | -$6.09M derived: sum of 3 quarters · filed 2022-08-11 | -$7.73M derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | -$1.88M 10-Q · filed 2022-05-12 | -$4.01M derived: sum of 2 quarters · filed 2022-05-12 | -$5.65M derived: sum of 3 quarters · filed 2022-05-12 | -$7.10M derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | -$3.77M derived: sum of 2 quarters · filed 2022-03-24 | -$5.21M derived: sum of 3 quarters · filed 2022-03-24 | -$6.30M 10-K · filed 2022-03-24 | ||
| 2020-09-30 | -$1.64M 10-Q · filed 2021-11-12 | -$3.09M derived: sum of 2 quarters · filed 2021-11-12 | -$4.18M 10-Q · filed 2021-11-12 | -$5.38M derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2020-06-30 | -$1.45M 10-Q · filed 2021-11-12 | -$2.54M 10-Q · filed 2021-08-12 | -$3.74M derived: sum of 3 quarters · filed 2021-11-12 | -$4.48M derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2020-03-31 | -$1.09M 10-Q · filed 2021-11-12 | -$2.30M derived: sum of 2 quarters · filed 2021-11-12 | -$3.03M derived: sum of 3 quarters · filed 2021-11-12 | -$3.94M derived: sum of 4 quarters · filed 2021-11-12 | ||
| 2019-12-31 | -$1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$1.94M derived: sum of 2 quarters · filed 2021-03-25 | -$2.85M derived: sum of 3 quarters · filed 2021-03-25 | -$4.22M 10-K · filed 2021-03-25 | ||
| 2019-09-30 | -$736.08K 10-Q · filed 2020-11-12 | -$1.64M derived: sum of 2 quarters · filed 2020-11-12 | -$3.02M 10-Q · filed 2020-11-12 | -$3.91M derived: sum of 4 quarters · filed 2020-11-12 | ||
| 2019-06-30 | -$905.70K 10-Q · filed 2020-11-12 | -$2.28M 10-Q · filed 2020-08-06 | -$3.17M derived: sum of 3 quarters · filed 2020-11-12 | -$3.81M derived: sum of 4 quarters · filed 2020-11-12 | ||
| 2019-03-31 | -$1.38M 10-Q · filed 2020-11-12 | -$2.27M derived: sum of 2 quarters · filed 2020-11-12 | -$2.91M derived: sum of 3 quarters · filed 2020-11-12 | -$3.55M derived: sum of 4 quarters · filed 2020-11-12 | ||
| 2018-12-31 | -$890.46K 10-Q · filed 2019-11-12 | -$1.53M derived: sum of 2 quarters · filed 2019-11-12 | -$2.17M derived: sum of 3 quarters · filed 2019-11-12 | -$3.23M 10-K · filed 2020-03-27 | ||
| 2018-09-30 | -$640.18K 10-Q · filed 2019-11-12 | -$1.28M derived: sum of 2 quarters · filed 2019-11-12 | -$2.34M 10-Q · filed 2019-11-12 | -$2.87M derived: sum of 4 quarters · filed 2019-11-12 | ||
| 2018-06-30 | -$640.18K 10-Q · filed 2019-11-12 | -$820.94K 10-Q · filed 2018-08-09 | -$1.70M 10-Q · filed 2019-08-08 | -$2.23M derived: sum of 3 quarters · filed 2019-11-12 | -$17.11M derived: sum of 4 quarters · filed 2019-11-12 | |
| 2018-03-31 | -$876.35K 10-Q · filed 2019-11-12 | -$1.59M derived: sum of 2 quarters · filed 2019-11-12 | -$16.47M derived: sum of 3 quarters · filed 2019-11-12 | -$17.06M derived: sum of 4 quarters · filed 2019-11-12 | ||
| 2017-12-31 | -$713.58K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$15.59M derived: sum of 2 quarters · filed 2019-02-26 | -$16.18M derived: sum of 3 quarters · filed 2019-02-26 | -$16.55M 10-K · filed 2019-02-26 | ||
| 2017-09-30 | -$14.88M 10-Q · filed 2018-11-09 | -$15.47M derived: sum of 2 quarters · filed 2018-11-09 | -$15.84M 10-Q · filed 2018-11-09 | |||
| 2017-06-30 | -$591.44K 10-Q · filed 2018-08-09 | -$964.36K 10-Q · filed 2018-08-09 | ||||
| 2017-03-31 | -$372.92K 10-Q · filed 2018-05-11 | |||||
| 2016-12-31 | -$1.19M 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |